Cardiovascular remodeling and the peripheral serotonergic system

详细信息    查看全文

• 作者：Estelle Ayme-Dietrich^a ; Gaë ; lle Aubertin-Kirch^a ; Luc Maroteaux^b ; Laurent Monassier^a ; ^{laurent.monassier@unistra.fr}
• 关键词：Serotonin ; Cardiac remodeling ; Cardiac hypertrophy ; Valve degeneration ; Fibrosis
• 刊名：Archives of Cardiovascular Diseases
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：110
• 期：1
• 页码：51-59
• 全文大小：984 K
• 卷排序：110

文摘

Plasma 5-hydroxytryptamine (5-HT; serotonin), released from blood platelets, plays a major role in the human cardiovascular system. Besides the effect of endogenous serotonin, many drugs targeting serotonergic receptors are widely used in the general population (antiobesity agents, antidepressants, antipsychotics, antimigraine agents), and may enhance the cardiovascular risk. Depending on the type of serotonin receptor activated and its location, the use of these compounds triggers acute and chronic effects. The acute cardiovascular response to 5-HT, named the Bezold-Jarish reflex, leads to intense bradycardia associated with atrioventricular block, and involves 5-HT3, 5-HT1B/1D, 5-HT7 and 5-HT2A/2B receptors. The chronic contribution of 5-HT and its receptors (5-HT4 and 5-HT2A/2B) in cardiovascular tissue remodeling, with a particular emphasis on cardiac hypertrophy, fibrosis and valve degeneration, will be explored in this review. Finally, through the analysis of the effects of sarpogrelate, some new aspects of 5-HT2A receptor pharmacology in vasomotor tone regulation and the interaction between endothelial and smooth muscle cells will also be discussed. The aim of this review is to emphasize the cardiac side effects caused by serotonin receptor activation, and to highlight their possible prevention by the development of new drugs targeting this system.